Abstract
The glycoprotein (GP) IIb‐IIIa inhibitor eptifibatide (INTEGRILIN®, COR Therapeutics, Inc., South San Francisco, California, and Key Pharmaceuticals, Inc., Kenilworth, New Jersey) is a novel and highly potent antithrombotic agent indicated for the management of patients with non‐ST‐segment elevation acute coronary syndromes (ACS) and those undergoing percutaneous coronary intervention. The approval of eptifibatide for non‐ST‐segment elevation ACS was based on the positive results of the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. With enrollment of almost 11,000 patients, not only is the PURSUIT trial the largest trial of a GP IIb‐IIIa inhibitor to date, but it is also the largest clinical study ever conducted in patients with non‐ST‐segment elevation ACS. The key feature of the PURSUIT trial is that patient management closely resembled standard clinical practice, because decisions about the use and timing of invasive cardiac procedures were made by the individual physicians rather than being prespecified in the study protocol. Eptifibatide therapy was associated with a significant reduction in the incidence of the primary endpoint—a composite of death or myocardial infarction at 30 days (14.2 vs. 15.7% in the placebo group; p = 0.042). Of importance is the fact that the beneficial effect of eptifibatide was independent of the management strategy pursued during study drug infusion (invasive or conservative), and it was achieved with few major safety concerns. These findings demonstrate that the use of eptifibatide should be considered for all patients presenting with signs and symptoms of intermediate‐ to high‐risk non‐ST‐segment elevation ACS.
Full Text
The Full Text of this article is available as a PDF (1.4 MB).
References
- 1. Armstrong PW, Fu Y, Chang WC, Topol EJ, Granger CB, Betriu A, Van de Werf F, Lee KL, Califf RM: Acute coronary syndromes in the GUSTO‐IIb trial: Prognostic insights and impact of recurrent ischemia. Circulation 1998; 98: 1860–1868 [DOI] [PubMed] [Google Scholar]
- 2. Savonitto S, Ardissino D, Granger CB, Morando G, Prando MD, Mafrici A, Cavallini C, Melandri G, Thompson TD, Vahanian A, Ohman EM, Califf RM, Van de Werf F, Topol EJ: Prognostic value of the admission electrocardiogram in acute coronary syndromes. J Am Med Assoc 1999; 281: 707–713 [DOI] [PubMed] [Google Scholar]
- 3. The TIMI IIIB Investigators : Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non‐Q‐wave myocardial infarction: Results of the TIMI IIIB trial. Circulation 1994; 89: 1545–1556 [DOI] [PubMed] [Google Scholar]
- 4. Lincoff AM, Califf RM, Topol EJ: Platelet glycoprotein Ilb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol 2000; 35: 1103–1115 [DOI] [PubMed] [Google Scholar]
- 5. Lefkovits J, Plow EF, Topol EJ: Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553–1559 [DOI] [PubMed] [Google Scholar]
- 6. White HD: Unmet therapeutic needs in the management of acute ischemia. Am J Cardiol 1997; 80 (suppl 4A): 2B–10B [DOI] [PubMed] [Google Scholar]
- 7. Scarborough RM: Development of eptifibatide. Am Heart J 1999; 138: 1093–1104 [DOI] [PubMed] [Google Scholar]
- 8. The PURSUIT Trial Investigators : Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436–443 [DOI] [PubMed] [Google Scholar]
- 9. Harrington RA: Design and methodology of the PURSUIT trial: Evaluating eptifibatide for acute ischemic coronary syndromes. Am J Cardiol 1997; 80 (suppl 4A): 34B–38B [DOI] [PubMed] [Google Scholar]
- 10. The CAPTURE Investigators : Randomised placebo‐controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997; 349: 1429–1435 [PubMed] [Google Scholar]
- 11. The PRISM‐PLUS Study Investigators : Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non‐Q‐wave myocardial infarction. N Engl J Med 1998; 338: 1488–1497 [DOI] [PubMed] [Google Scholar]
- 12. Mahaffey KW, Harrington RA, Simoons ML, Granger CB, Graffagnino C, Alberts MJ, Laskowitz DT, Miller JM, Sloan MA, Berdan LG, MacAulay CM, Lincoff AM, Deckers J, Topol EJ, Califf RM: Stroke in patients with acute coronary syndromes: Incidence and outcomes in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial. Circulation 1999; 99: 2371–2377 [DOI] [PubMed] [Google Scholar]
- 13. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML: Thrombolysis in Myocardial Infarction (TIMI) trial—phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1–11 [DOI] [PubMed] [Google Scholar]
- 14. McClure MW, Berkowitz SD, Sparapani R, Tuttle R, Kleiman NS, Berdan LG, Lincoff AM, Deckers J, Diaz R, Karsch KR, Gretler D, Kitt M, Simoons M, Topol EJ, Califf RM, Harrington RA, for the PURSUIT Investigators: Clinical significance of thrombocytopenia during a non‐ST‐elevation acute coronary syndrome. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial experience. Circulation 1999; 99: 2892–2900 [DOI] [PubMed] [Google Scholar]
- 15. Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers JW, Simoons ML, Guerci A, Hochman JS, Wilcox RG, Kitt MM, Eisenberg PR, Califf RM, Topol EJ, Karsh K, Ruzyllo W, Stepinska M, Widimsky P, Boland JB, Armstrong PW, On behalf of the PURSUIT Investigators: Prior aspirin use predicts worse outcomes in patients with non‐ST‐elevation acute coronary syndromes. Am J Cardiol 1999; 83: 1147–1151 [DOI] [PubMed] [Google Scholar]
- 16. Cohen M, Ferguson JJ III, Harrington RA: Trials of glycoprotein IIb‐IIIa inhibitors in non‐ST‐segment elevation acute coronary syndromes: Applicability to the practice of medicine in the United States. Clin Cardiol 1999; 22 (suppl VI): VI‐2–VI‐12 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Lorenz TJ, Greenberg S, Kitt MM: Regional and gender differences in the access to early percutaneous coronary intervention for non‐ST‐segment elevation acute coronary syndromes: Experience from the PURSUIT trial with glycoprotein IIb‐IIIa inhibitor eptifibatide (INTEGRILIN®) (abstr). J Am Coll Cardiol 2000; 35 (suppl A): 87A [Google Scholar]
- 18. The GUSTO IIb Investigators : A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775–782 [DOI] [PubMed] [Google Scholar]
- 19. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F: A comparison of low‐molecular‐weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447–452 [DOI] [PubMed] [Google Scholar]
- 20. The PARAGON Investigators : International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998; 97: 2386–2395 [DOI] [PubMed] [Google Scholar]
- 21. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E: Enoxaparin prevents death and cardiac ischemic events in unstable angina/non‐Q‐wave myocardial infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation 1999; 100: 1593–1601 [DOI] [PubMed] [Google Scholar]
- 22. FRagmin and Fast Revascularisation during InStability in Coronary artery disease (FRISC II) Investigators : Long‐term low‐molecularmass heparin in unstable coronary‐artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 701–707 [PubMed] [Google Scholar]
- 23. Harrington RA, Lincoff AM, Berdan LG, MacAulay C, Kint P‐P, Mahaffey KW, Kitt MM, Simoons ML, Califf RM: Maintenance of clinical benefit at six‐months in patients treated with platelet glycoprotein IIb/IIIa inhibitor eptifibatide versus placebo during an acute ischemic coronary event (abstr). Circulation 1998; 98 (suppl): I–359 [Google Scholar]
- 24. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, Akkerhuis KM, Harrington RA, Deckers JW, Armstrong PW, Lincoff AM, Califf RM, Topol EJ, Simoons ML: Predictors of outcome in patients with acute coronary syndromes without persistent ST‐segment elevation. Results from an international trial of 9461 patients. Circulation 2000; 101: 2557–2567 [DOI] [PubMed] [Google Scholar]
- 25. Kleiman NS, Lincoff AM, Flaker GC, Pieper KS, Wilcox RG, Berdan LG, Lorenz TJ, Cokkinos DV, Simoons ML, Boersma E, Topol EJ, Califf RM, Harrington RA, for the PURSUIT Investigators: Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. Circulation 2000; 101: 751–757 [DOI] [PubMed] [Google Scholar]
- 26. Lorenz TJ, Greenberg S, Kleiman NS, Boersma E, Lincoff MA, Harrington RA, Kitt MM, Simoons ML: Eptifibatide during immediate percutaneous coronary intervention (PCI) in the acute coronary syndromes (ACS): Findings from the PURSUIT study (abstr). J Am Coll Cardiol 1999; 33 (suppl A): 72A [Google Scholar]
- 27. Marso SP, Bhatt DL, Roe MT, Houghtaling PL, Lorenz T, Labinaz M: Enhanced efficacy of eptifibatide pre‐treatment in patients with acute coronary syndromes undergoing in‐hospital coronary bypass surgery (abstr). Circulation 1999; 100 (suppl): I–433 [Google Scholar]
- 28. Greenbaum AB, Harrington RA, Hudson MP, Miller GP, MacAulay CM, Berdan LG, Guerci A, Kitt MM, Califf RM, Ohman EM: Enhanced benefit of eptifibatide in patients with acute coronary syndromes using a seamless transition from community hospitals to tertiary care centers (abstr). Circulation 1998; 98 (suppl): I–561 [Google Scholar]
- 29. Ledley GS: Managing unstable angina: New considerations for interventional practice in the era of glycoprotein IIb‐IIIa inhibitors. Today's Therapeutic Trends 1999; 17: 321–343 [Google Scholar]
- 30. Alexander JH, Sparapani RA, Mahaffey KW, Boersma E, Lincoff AM, Wilcox RG, Kitt MM, Simoons ML, Topol EJ, Califf RM, Harrington RA: Eptifibatide reduces the size and incidence of myocardial infarction in patients with non‐ST‐elevation acute coronary syndromes (abstr). J Am Coll Cardiol 1999; 33 (suppl A): 331A [Google Scholar]
- 31. Alexander JH, Sparapani RA, Mahaffey KW, Deckers JW, Newby LK, Ohman EM, Corbalàn R, Chierchia SL, Boland JB, Simoons ML, Califf RM, Topol EJ, Harrington RA, for the PURSUIT Steering Committee : Association between minor elevations of creatine kinase‐MB level and mortality in patients with acute coronary syndromes without ST‐segment elevation. J Am Med Assoc 2000; 283: 347–353 [DOI] [PubMed] [Google Scholar]
- 32. Fintel DJ, Greenberg S, Lorenz TJ, Kitt MM: Myocardial infarction during the first 72 hours of hospitalization is a predictor of late‐term mortality in patients presenting with non‐ST‐elevation acute coronary syndromes (abstr). J Am Coll Cardiol 2000; 35 (suppl A): 375A [Google Scholar]
- 33. Bhatt DL, Marso SP, Houghtaling P, Labinaz M, Lauer MA: Does earlier administration of eptifibatide reduce death and MI in patients with acute coronary syndromes? (abstr). Circulation 1998; 98 (suppl): I‐560–I‐561 [Google Scholar]
- 34. Braunwald E, Jones RH, Mark DB, Brown J, Brown L, Cheitlin MD, Concannon CA, Cowan M, Edwards C, Fuster V, Goldman L, Green LA, Grines CL, Lytle BW, McCauley KM, Mushlin AI, Rose GC, Smith EEI, Swain JA, Topol EJ, Willerson JT: Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. Circulation 1994; 90: 613–622 [DOI] [PubMed] [Google Scholar]